Skip to main content
Medical Reference · Condition Monograph

Hodgkin Disease

호지킨병

A type of blood cancer that begins in the lymph nodes, now also called "Hodgkin lymphoma." Treatment outcomes are relatively good, but precise diagnosis and staging are the starting point for treatment.

History

Hodgkin disease, now also called "Hodgkin lymphoma," is a type of blood cancer that begins in the lymph nodes. The disease was named after the British physician Thomas Hodgkin, who in the early 19th century observed patients with abnormalities of the lymph nodes and spleen and described it as a distinct disease. At the time, infectious diseases such as tuberculosis and syphilis could also enlarge lymph nodes, so it was very difficult to tell whether these patients had the same disease or different diseases.

Later, as pathology advanced in the late 19th and early 20th centuries, it became known that characteristic large cancer cells could be observed under the microscope. These cells are now called "Reed–Sternberg cells" and are the key clue for diagnosing Hodgkin lymphoma. In the early 20th century, observations followed that X-ray therapy could shrink lymph node masses, and in the mid-20th century, as methods of treatment combining several anticancer drugs were developed, it began to become a curable cancer.

In particular, Hodgkin lymphoma is considered one of the representative cancers in which advances in chemotherapy and radiation therapy have clearly led to "improved survival rates." As treatment has improved, "cure" has now become the goal of treatment in many cases, and at the same time, as the number of long-term survivors has grown, research on adjusting treatment intensity to reduce aftereffects of treatment (second cancers, heart and lung complications, infertility, and others) has also become active.

Causes

The "exact" cause of Hodgkin lymphoma has not yet been definitively explained as a single factor. However, there are factors known to increase risk. The one most often mentioned is infection with Epstein–Barr virus (EBV). EBV is a common virus, and most people are infected at some point in their lives, but in some cases it is known that it may be associated with the development of lymphoma through interaction with the immune system.

A weakened immune state is also a risk factor. When immune surveillance is reduced, as when immunity is weakened by human immunodeficiency virus (HIV) infection or when immunosuppressants are used for a long period after organ transplantation, the risk of lymphoma can rise. In addition, there are reports that the risk increases somewhat when a family member has Hodgkin lymphoma, raising the possibility that genetic factors and shared environmental factors act together.

The important point is that having these risk factors does not necessarily mean Hodgkin lymphoma will develop, and conversely, it can develop even without any particular risk factor. Therefore, rather than attributing the cause to "a single specific lifestyle habit," it is generally understood that the disease can arise when infection (especially EBV), immune status, and genetic predisposition interlock in various ways.

Genetic Epidemiology

Genetic epidemiology is an approach that examines "how much the inborn genetic differences between people change the risk of developing Hodgkin lymphoma." Hodgkin lymphoma is known to be strongly influenced by environmental and infectious factors, but because it is observed somewhat more commonly within families, genetic predisposition has also been studied steadily.

Notably, there are reports that the risk increases in family members who share many genes, such as siblings or identical twins. This is interpreted to mean not that a specific gene directly "creates Hodgkin lymphoma," but that it may increase risk through constitutional differences such as vulnerability in immune responses or to viral infection and regulation of inflammatory responses.

There are also studies showing that differences in immune-related genes, especially genes involved in the process by which the immune system recognizes foreign invaders, such as human leukocyte antigen (HLA), are associated with some subtypes. There is also a view that the influence of these immune genes may be more prominent in EBV-related Hodgkin lymphoma.

In current clinical practice, it is not yet possible for the general public to precisely predict the risk of Hodgkin lymphoma through genetic testing, nor are specific genetic tests "recommended" for prevention. The most practical response is to see a physician promptly for evaluation when there are persistent lymph node enlargement or systemic symptoms ("B symptoms") such as fever, night sweats, and weight loss.

General Epidemiology

Hodgkin lymphoma is a cancer that begins in the lymph nodes and lymphatic system, and it occupies a relatively distinctive place among all lymphomas. In some countries, a "bimodal" age distribution is described, with incidence increasing once in young adults (roughly from the late teens to the early 30s) and again in older adults (especially after the 60s and 70s). By sex, a tendency to be slightly more common in men than in women is often reported.

The disease often begins in the lymph nodes of the neck or chest (mediastinum). Even when it spreads to multiple lymph node sites, it is described as tending to spread to adjacent lymph nodes in a relatively predictable way compared with non-Hodgkin lymphoma, and this characteristic is reflected in staging and treatment planning.

In addition, the proportion related to EBV and the distribution of subtypes can vary by region and age. Because the risk of developing it is known to increase in immunocompromised states (for example, HIV infection), immune status is also treated as an important variable epidemiologically.

In conclusion, Hodgkin lymphoma is not a common cancer, but treatment outcomes are relatively good and it can also appear in young people, so "not missing the early symptoms" is important.

Pathogenesis

Hodgkin lymphoma begins in lymphocytes (white blood cells responsible for immunity), but unlike other lymphomas, the proportion of actual cancer cells within the tumor tissue is often low. The characteristic cancer cell is the Reed–Sternberg cell, which is generally understood to originate from the B-lymphocyte (the lymphocyte that makes antibodies) lineage. The cancer cells attract surrounding normal immune cells and create an inflammatory response, forming a mass that enlarges the lymph node.

Why these cancer cells arise has not been clearly explained by a single factor, but it is thought that DNA damage in the cells, abnormalities of immune regulation, and, in some cases, EBV infection may act in combination. One explanation is that EBV can infect B cells, and if infected cells are not removed normally or growth signals are abnormally activated, this can lead to a tumor.

Because the cancer cells of Hodgkin lymphoma tend to survive through "interaction" with surrounding immune cells, the problem is not simply one of the cancer cells alone; the microenvironment (the immune environment surrounding the tumor) plays an important role in maintaining and advancing the disease. This understanding is also reflected in treatment, and in some patients, immunotherapy such as immune checkpoint inhibitors is used. The pathogenesis can be explained as "emergence of abnormal B-lymphocyte cells → influence of immune and viral factors → maintenance and expansion of lesions through interaction with the tumor microenvironment."

Symptoms

The most common symptom of Hodgkin lymphoma is lymph node enlargement with little or no pain. It may begin as a lump that can be felt in the neck, armpit, or groin, and it may start with one or two nodes and grow gradually. When the mediastinal lymph nodes in the chest (inside the chest) enlarge, cough, chest discomfort, or a feeling of shortness of breath may appear even if no lump is visible on the outside.

Another important group of symptoms is "B symptoms." B symptoms refer to systemic symptoms related to cancer, mainly including fever of unknown cause, night sweats heavy enough to require changing clothes, and unintentional weight loss. Because these symptoms are often reflected in the assessment of stage and prognosis, it is important not to dismiss them as a simple cold or stress.

In addition, fatigue, general weakness, loss of appetite, and itching of the skin (pruritus) may accompany the disease. In some people, an unusual pattern of pain in the lymph node area after drinking alcohol has been described, but it is not a common symptom.

"Painless lymph node enlargement + unexplained systemic symptoms (B symptoms)" are the key symptoms that raise suspicion of Hodgkin lymphoma.

Signs

Signs are objective clues confirmed by tests or examination. On physical examination, enlargement of the cervical, axillary, or inguinal lymph nodes is common, and a mediastinal mass may be seen on chest imaging. Enlargement of the spleen or liver (splenomegaly, hepatomegaly) may also be present.

Blood tests may show nonspecific abnormalities. For example, anemia, changes in white blood cells, and changes in platelets may be seen, and an elevated erythrocyte sedimentation rate (ESR) reflecting an inflammatory response or elevated lactate dehydrogenase (LDH) may be observed. However, Hodgkin lymphoma cannot be confirmed by these tests alone; they serve as a reference for understanding disease activity and general condition.

On imaging, computed tomography (CT) or positron emission tomography (PET) is used to check for involvement of multiple lymph node groups and involvement of organs such as the spleen. After treatment, PET is sometimes used to help determine whether remaining lesions are "active" or simply scar tissue.

The key signs of Hodgkin lymphoma are "persistent lymph node enlargement in a specific area," lymph node involvement confirmed on imaging, and characteristic cells observed on biopsy.

Screening

For Hodgkin lymphoma, no standard screening test for the general population (for example, a test that must be done at a routine checkup) has been established. This is because the disease itself is not very common in the population as a whole, and there is a lack of tests that are both simple and accurate enough to be used for screening. In addition, because lymph node enlargement frequently appears in common conditions such as infections, screening could increase unnecessary detailed testing.

Instead, the realistic method of "early detection" is symptom-based evaluation. When a lymph node persists without shrinking for 2–4 weeks or more or keeps growing, when B symptoms (fever, night sweats, weight loss) accompany it, or when unexplained lymph node enlargement occurs in an immunocompromised state (such as HIV), evaluation through a medical visit effectively serves the role of screening.

Routine blood tests or a simple chest X-ray may provide clues, but normal results cannot rule out Hodgkin lymphoma. Therefore, rather than "a specific test," the key is "connecting to specialist evaluation when warning signs persist."

Diagnosis

The key to diagnosing Hodgkin lymphoma is a lymph node biopsy. The location of lymph node enlargement, its duration, whether it is painful, and the presence of B symptoms are checked through history and examination, and general condition is assessed with basic blood tests. Then imaging tests are used to determine the distribution of lymph nodes and whether organs are involved.

To confirm the diagnosis, an "excisional biopsy" of the lymph node is performed whenever possible to obtain sufficient tissue. Because a test using only a fine needle sometimes cannot adequately show the structure needed for diagnosis, excisional biopsy is preferred. Reed–Sternberg cells are identified on pathological examination, and the subtype is classified using immunohistochemistry (IHC).

Staging is mainly performed using CT and PET-CT. PET helps find small or active lesions and is also important for assessing treatment response. Depending on the situation, a bone marrow examination may be considered, and before starting treatment, evaluations such as heart and lung function tests may be performed in preparation for chemotherapy.

"Clinical suspicion → determining the extent with imaging → confirmation by excisional lymph node biopsy → staging and treatment planning with PET/CT" is the basic flow of diagnosis.

Treatment

Hodgkin lymphoma responds well to treatment, and cure is often the goal. Treatment varies depending on the stage (how far it has spread), risk level, and the patient's age and general condition, but the main pillar is chemotherapy, with radiation therapy added depending on the situation. In early stages, an approach of several cycles of chemotherapy followed by radiation therapy to the lesion sites may be used. In advanced stages, chemotherapy plays a larger role, and treatment intensity is sometimes adjusted while assessing treatment response with PET.

In cases of relapse or poor response to treatment, high-dose chemotherapy followed by autologous stem cell transplant (ASCT) may be considered. In addition, targeted therapy or immunotherapy is used in some patients. Immune checkpoint inhibitors such as PD-1 inhibitors can be a treatment option in certain situations.

As treatment has improved, reducing long-term side effects has also become important. Radiation therapy may be associated in the long term with thyroid disease, cardiovascular disease, and the risk of second cancers, so strategies to minimize the necessary field and dose have been developed. Chemotherapy may also be associated with infertility, infection risk, and heart and lung toxicity, so management before and after treatment is necessary.

Prognosis

Hodgkin lymphoma generally has a good prognosis, and cure can be expected in many patients. The prognosis is influenced by the stage, the presence of B symptoms, the size of the tumor (especially a chest mass), blood test findings, and age and general condition. In early stages, the treatment success rate is very high, and even in advanced stages, long-term survival is possible when treatment strategies are applied well.

PET is important in assessing treatment response because, even if a mass remains visible on imaging after treatment, it is necessary to distinguish whether it is living cancer or scar tissue. When activity on PET decreases, it is often interpreted as indicating a better prognosis.

As the number of long-term survivors has increased, there has been a stronger trend toward evaluating prognosis not only by "survival" but also by "quality of life after treatment." Because second cancers, cardiovascular disease, reduced lung function, thyroid disease, and other conditions can appear years to decades after treatment, regular follow-up and health management are important.

Prevention

It is difficult to say that Hodgkin lymphoma can be reliably prevented by changing any one specific lifestyle habit. However, because factors that increase risk are known, realistic prevention focuses on "reducing factors that harm immunity and checking warning signs early."

For example, preventing HIV infection and, for those who have HIV, maintaining immune function through treatment help manage the risk of lymphoma. When an immunocompromised state is unavoidable, as in people using immunosuppressants after organ transplantation, it is important not to miss lymph node changes or systemic symptoms through regular medical visits.

EBV is so common that it is difficult to avoid completely in daily life, but "immune status" rather than the infection itself is considered the important variable. Therefore, lifestyle habits such as a balanced diet, sufficient sleep, and reducing excessive drinking and smoking can help maintain overall health and immunity.

Above all, the most important preventive action is early evaluation. If a lump in the neck, armpit, or groin persists for 2–4 weeks or more or grows larger, or if B symptoms such as fever, night sweats, and weight loss accompany it, getting tested is the most realistic and powerful "preventive" action.

This content is provided for general medical information only and does not replace individual diagnosis or treatment. If symptoms persist, please consult a medical professional.